COX-2-IN-9

• UNSPSC Description:

  COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity[1].

• Target Antigen:

  COX

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cox-2-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C/C(C1=CC=C(C=C1)NC(CSC2=NN(C(C3=CC=CC=C3)=N2)C4=CC=C(C=C4)S(C)(=O)=O)=O)=N\O

• Molecular Weight:

  521.61

• References & Citations:

  [1]Abdellatif KRA, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study [published online ahead of print, 2022 Jan 19]. Bioorg Chem. 2022;120:105627.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported